Gapping down
In reaction to earnings/guidance:
- ADBE -3.4%
Other news:
- RYTM -5.1% (FDA issues CRL for the sNDA for setmelanotide in Alström syndrome; FDA approves sNDA for IMCIVREE; also enters into Revenue Interest Financing Agreement with HealthCare Royalty for a total investment up to $100 mln)
- CO -2.3% (FDA recently cleared Cellenkos' IND application for CK0804 as add on therapy to Ruxolitinib)
- FTI -2.2% (awarded a significant contract by TotalEnergies EP Angola)
- OWL -1.5% (files $1 bln mixed securities shelf offering)
- TRGP -0.8% (to acquire Lucid Energy for $3.55 bln; also updates 2022 standalone outlook)
Analyst comments:
- DFH -5.1% (downgraded to Underperform from Neutral at BofA Securities)
- AEO -1.7% (downgraded to Neutral from Buy at B. Riley Securities)
- DOW -0.8% (downgraded to Neutral from Buy at Citigroup)
- CF -0.7% (downgraded to Neutral from Buy at Citigroup)